<?xml version="1.0" encoding="UTF-8"?>
<p>Modern directly acting antiviral (DAA) therapy for HCV facilitates virological cure at a favorable safety and drug tolerability profile in nearly all patients[
 <xref rid="pone.0229239.ref003" ref-type="bibr">3</xref>â€“
 <xref rid="pone.0229239.ref008" ref-type="bibr">8</xref>]. The latest pangenotypic treatment regimens induce excellent SVR (sustained virologic response) rates independent of HCV-genotype (GT), even in former difficult-to-treat populations including patients with cirrhosis, pretreated subjects and HIV-coinfected patients[
 <xref rid="pone.0229239.ref009" ref-type="bibr">9</xref>]. The consecutive decrease in HCV-associated HCC and decompensated cirrhosis lead to a recomposition of liver transplant waitlists with an increased donor organ availability for patients suffering from other entities of liver disease[
 <xref rid="pone.0229239.ref010" ref-type="bibr">10</xref>]. Unfortunately, in many countries of the world access to pangenotypic DAA therapy is still limited by the high treatment costs[
 <xref rid="pone.0229239.ref011" ref-type="bibr">11</xref>].
</p>
